-
1
-
-
4444326818
-
Follicular lymphoma international prognostic index
-
Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
-
(2004)
Blood
, vol.104
, pp. 1258-1265
-
-
Solal-Celigny, P.1
Roy, P.2
Colombat, P.3
-
2
-
-
33748323249
-
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome
-
Buske C, Hoster E, Dreyling M, Hasford J et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
-
(2006)
Blood
, vol.108
, pp. 1504-1508
-
-
Buske, C.1
Hoster, E.2
Dreyling, M.3
Hasford, J.4
-
3
-
-
8644252736
-
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
-
Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
-
(2004)
N Engl J Med
, vol.351
, pp. 2159-2169
-
-
Dave, S.S.1
Wright, G.2
Tan, B.3
-
4
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
Cheson B, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
-
(2007)
J Clin Oncol
, vol.25
, pp. 579-586
-
-
Cheson, B.1
Pfistner, B.2
Juweid, M.E.3
-
5
-
-
0006987727
-
Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University
-
MacManus PM, Hoppe RT. Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282-1290.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1282-1290
-
-
MacManus, P.M.1
Hoppe, R.T.2
-
6
-
-
13244270361
-
CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
-
Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
-
(2005)
Blood
, vol.105
, pp. 1417-1423
-
-
Marcus, R.1
Imrie, K.2
Belch, A.3
-
7
-
-
28544435078
-
Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
-
Hiddemann W, Kneba M, Dreyling M et al. Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2005; 106: 3725-3732.
-
(2005)
Blood
, vol.106
, pp. 3725-3732
-
-
Hiddemann, W.1
Kneba, M.2
Dreyling, M.3
-
8
-
-
2942567554
-
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4 schedule
-
Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood 2004; 103: 4416-4423.
-
(2004)
Blood
, vol.103
, pp. 4416-4423
-
-
Ghielmini, M.1
Schmitz, S.F.2
Cogliatti, S.B.3
-
9
-
-
0642281444
-
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
-
Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918-3927.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3918-3927
-
-
Schouten, H.C.1
Qian, W.2
Kvaloy, S.3
-
10
-
-
55949118446
-
90Y-Ibritumomab Tiuxetan after first remission in advanced follicular lymphoma
-
90Y-Ibritumomab Tiuxetan after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5156-5164
-
-
Morschhauser, F.1
Radford, J.2
Van Hoof, A.3
-
11
-
-
33845704776
-
Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma-role of radioimmunotherapy
-
Dreyling M, Trumper L, von Schilling C et al. Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma-role of radioimmunotherapy. Ann Hematol 2007; 86: 81-87.
-
(2007)
Ann Hematol
, vol.86
, pp. 81-87
-
-
Dreyling, M.1
Trumper, L.2
von Schilling, C.3
-
12
-
-
33749545033
-
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial
-
van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295-3301.
-
(2006)
Blood
, vol.108
, pp. 3295-3301
-
-
van Oers, M.H.1
Klasa, R.2
Marcus, R.E.3
-
13
-
-
33845515497
-
-
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
-
Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003-4008.
-
(2006)
Blood
, vol.108
, pp. 4003-4008
-
-
Forstpointner, R.1
Unterhalt, M.2
Dreyling, M.3
|